text: Clinical Profile and Short Term Outcome of Children With SARS CoV 2 Related Multisystem Inflammatory Syndrome MIS C Treated With Pulse Methylprednisolone To study the clinical profile and outcome of children with MIS C treated with methylprednisolone pulse therapy and or intravenous immunoglobulin IVIG This prospective observational study included children satisfying CDC MIS C criteria admitted from September to November 2020 Primary outcome was persistence of fever beyond 36 hours after start of immunomodulation therapy Secondary outcomes included duration of ICU stay mortality need for repeat immunomodulation time to normalization of CRP and persistence of coronary abnormalities at 2 weeks Study population included 32 patients with MIS C with median IQR age of 7 5 5 9 5 years The proportion of children with gastrointestinal symptoms was 27 84 cardiac was 29 91 and coronary artery dilatation was 11 34 Pulse methylprednisolone and intravenous immunoglobulin were used as first line therapy in 26 81 and 6 19 patients respec tively Treatment failure was observed in 2 26 patients in methylprednisolone group and 2 6 patients in IVIG group C reactive protein levels less than 60mg L by day 3 was seen in 17 74 in methylprednisolone group and 2 25 in IVIG group P 0 014 There was no mortality At 2 weeks follow up coronary artery dilatation persisted in 4 in methylprednisolone group and 1 in IVIG group In patients with SARS CoV 2 related MIS C methylprednisolone pulse therapy was associated with favorable short term outcomes 